However, as a recent study described that CDX2 loss through demethylation and HDAC inhibition is an adverse prognostic factor and linked to molecular features of the serrated pathway [68], CDX2 may act as an oncogene in tumors with a high expression of CDX2, but this is not necessarily applicable to all cases of CRC with chr13q12.2 aberration. The gene discussed is HDAC9; the disease is colorectal carcinoma.